@article{3adbfe66e340483e9bc692f28c28edeb,
title = "Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis",
keywords = "cirrhosis, decompensated, direct-acting antivirals, hepatitis C virus, retreatment, salvage therapy, sofosbuvir, velpatasvir, voxilaprevir",
author = "Sonalie Patel and Martin, {Michelle T.} and Flamm, {Steven L.}",
note = "Funding Information: SF serves on the speakers{\textquoteright} bureau, advises and receives grants from AbbVie and Gilead. MTM serves on the speakers{\textquoteright} bureau for AbbVie, has received grant funding from Gilead and Merck, served on the advisory board for AbbVie and Gilead, and is a minor shareholder of AbbVie, Gilead and Merck stock. SP serves on the speakers{\textquoteright} bureau for AbbVie and Gilead. ",
year = "2021",
month = dec,
doi = "10.1111/liv.15075",
language = "English (US)",
volume = "41",
pages = "3024--3027",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "12",
}
